
Opinion|Videos|December 11, 2024
Case 2: Low-Volume Recurrent mCSPC
Key Takeaways
Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.
Advertisement
Episodes in this series
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5














